
Bengaluru's deep-tech startup proposes ‘quantum' leap in cancer care
One among the 20-odd exhibitors at the recently concluded Quantum India Bengaluru Summit, Quantum Biosciences Private Limited's 'predictive tech" uses quantum biosensor to detect unique 'magnetic fingerprints' of oxidative stress in cells, allowing detection of tissue injury.
When his wife was diagnosed with cancer and had to undergo radiation therapy, Ravi Puvvala, Managing Director of Quantum Biosciences, who was earlier developing sensors for automotive industry, said he started exploring the possibility of using sensors to predict radiation-induced cardiotoxicity before irreversible damage.
'Radiation therapy is essential for treating cancer. But it kills not only the cancerous cells, also the good ones. This leads to long-term complications such as fatigue, cognitive decline, organ dysfunction and secondary cancers. It also potentially induces a heart disease or fibrosis. I watched my wife suffer because of some of these side effects," Puvvala told PTI.
Existing diagnostic tools, such as MRI, PET scans and blood biomarkers only detect harm after significant damage has already occurred, said Puvvala.
'So, I wanted to use my experience in building sensors, and, you know, explore technology, understand how to optimise this particular problem," added Puvvala.
He has been building technologies for the last 15 years, Puvvala said.
Things took a quantum leap when he partnered with the Netherlands-based QT Sense, led by another Indian, Deepak Veeragowda. QT Sense was formed to take forward the 15 years of academic research done in this area at the University of Groningen.
QT Sense's Quantum Nuova is a platform technology built for detecting quantum-level phenomena like subcellular free radicals and magnetic biomarkers.
'For the last two years, we have been researching various potential technologies for early stage diagnostics. We looked at classical sensors and quantum sensors, and we started quantum biosensors to leverage the potential of quantum sensors," said Puvvala.
Puvvala said while quantum biosensors can tell us that there exists a certain amount of stress at the subcellular level, the next step would be to understand how to read them.
'Further research is needed on how to map the cellular stress to a potential biomarker, only then we can say, okay, we made the prognosis," added Puvvala.
At the first edition of the Quantum India Bengaluru Summit, Puvvala reached out to researchers and other key stakeholders – including the government of Karnataka, academic institutions, acute care clinicians, pharmaceutical companies and hospitals — exploring this idea.
'To build this technology, we need a whole village. We need the engineering team, we need the medical team, and we need, you know, people like us, who can put all this together," said Puvvala.
According to him, they still need to do a lot of validation with respect to the sub cellular detection.
'For the first time we're able to actually go inside the cell and measure all kinds of things. But now we need to be able to make sense of what these measurements mean through clinical tests. So we need to conduct tests, and we need to be able to come up with a diagnostic mechanism," said Puvvala.
To this end, Puvvala said they would be spending the next two years working with various hospitals, both in India and abroad.
'We want to partner with cancer centres particularly, so we could get the necessary data," said Puvvala.
Quantum Biosciences is at present incubating its foundational research capabilities at Center for Cellular and Molecular Platforms (C-CAMP), an initiative of Department of Biotechnology, Ministry of Science and Technology, Government of India and at Center for Nano Science and Engineering (CeNSE) in Indian Institute of Science (IISc), Bengaluru, he added.
'We are also talking to other ecosystem leaders and state-level innovation programs to co-develop a shared infrastructure that bridges deep-science research with clinical applications," said Puvvala.
When they go past the 'very base-level mechanism", the technology, said Puvvala, would benefit not only oncology, but also nephrology, cardiovascular and neurodegenerative diseases.
top videos
View all
It could even help India's most basic struggle in providing health care, he added.
'One of the things I've heard at the conference is that most hospitals are overcrowded because the primary health care and the critical health care have been combined into one. The quantum biosensor could, you know, reduce the primary health care overload, by precisely identifying those cases that need critical care at a considerably lesser time," said Puvvala. PTI JR ROH
view comments
First Published:
August 03, 2025, 09:15 IST
News agency-feeds Bengaluru's deep-tech startup proposes 'quantum' leap in cancer care
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
15 minutes ago
- Time of India
Gujarat ranks 3rd in sickle cell disease
Ahmedabad: Data tabled in the Lok Sabha on Aug 1 indicated that Gujarat, with 28,178 identified sickle cell disease patients, has the third-largest patient base in the country. Odisha, with 96,484 cases, leads the table, and is followed by Madhya Pradesh with 30,762 cases, according to data shared by Union health minister J P Nadda in response to a question by Rajkumar Raot. What set Gujarat apart was that 90% of the cases (25,282) were recorded among the scheduled tribes (ST), including those in the particularly vulnerable tribal group (PVTG) category, which was the highest among Indian states and significantly higher compared to Odisha and Madhya Pradesh, according to the statistics up to the end of July 2025. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad The answer indicated that a total of 77.34 lakh citizens were screened to identify those with the condition. Under the National Sickle Cell Anaemia Elimination Mission (NSCAEM), persons with the condition are provided counselling regarding lifestyle, pre-marriage and pre-natal decisions and nutritional supplements among others. "The condition is marked by abnormal haemoglobin that makes red blood cells rigid and take the shape of a sickle. They often block the blood flow, leading to anaemia," a public health expert said. "Gujarat has recently launched a drive to understand the genetic makeup of the tribal population," the expert added.


Time of India
15 minutes ago
- Time of India
Hyd startup EON Space Labs raises $1.2M in Pre-Series A funding
Hyderabad: EON Space Labs, a Hyderabad-based deeptech startup focused on building advanced imaging technologies, has raised $1.2 million (approximately 10.5 crore) in a Pre-Series A funding round from MGF Kavachh and HHV Advanced Technologies, both of whom have also come on board as strategic partners. Tired of too many ads? go ad free now Set up in 2022 by three former LV Prasad Eye Institute (LVPEI) employees—Punit Badeka, Sanjay Kumar, and Manoj Kumar Gaddam—the T-Hub and IIT-Madras incubated EON is building miniaturised, high-resolution imaging systems for use in satellites, drones, unmanned aerial systems, and fixed ground platforms. The company was also a winner of one of the iDEX (Innovations for Defence Excellence) challenges and Ramaiah Evolute. The startup said the funds will support the launch of MIRA, touted as India's lightest high-res space telescope that is three to four times lighter and smaller than currently available space telescopes, later this year in a mission in collaboration with another Hyderabad-based startup, TakeMe2Space, that plans to launch India's first AI laboratory in space aboard Indian Space Research Organisation's launch vehicle. "MIRA is a monolithic telescope that has been manufactured using ultra-precision technology and is made from a single piece of fused silica glass, a space-qualified material. We reduced the moving components into one single block of pure silica glass," Badeka said. The fundraise will also help fund the launch of four new LUMIRA electro-optical and infrared (EO/IR or day & night) imaging systems designed for long-range detection of humans, vehicles, threats, and UAVs to enhance surveillance capabilities for both drone and ground-based platforms for surveillance and disaster response. Tired of too many ads? go ad free now The LUMIRA variants will target up to 85% of the use cases in the global EO/IR surveillance market, which is currently pegged at around $11 billion. EON already bagged multiple commercial orders for LUMIRA following successful proof of concept demonstrations.
&w=3840&q=100)

Business Standard
19 minutes ago
- Business Standard
Paytm waits on mkt cap rule to ramp up UPI: MD & CEO Vijay Shekhar Sharma
Financial technology major Paytm will further deepen its efforts to expand its footprint on India's real-time payments system — Unified Payments Interface (UPI) — once market share caps on third-party players come into effect, Managing Director and Chief Executive Officer Vijay Shekhar Sharma said on Tuesday. He added that consumer and merchant payments continue to present a growing opportunity, with the model's viability driven by merchant discount rates on select payment instruments and subscription-based revenues. '…we've restored the high UPI success rates that Paytm has long been known for. This has been made possible by the deep integration with our partner banks, our focus on technology, and the continued support from the National Payments Corporation of India (NPCI)… Once the market share caps are imposed, we are ready to move faster and go deeper on market expansion,' Sharma said in a letter to shareholders. The reference to a market share cap comes as NPCI, the apex retail payments body, has extended the deadline to implement a 30 per cent cap on third-party UPI apps by two years, until December 2026. NPCI is seeking to introduce a market cap to address potential concerns such as concentration risks among top players. PhonePe and Google Pay continue to dominate the UPI ecosystem, with both entities controlling more than 80 per cent of UPI transactions in volume terms. Sharma said that the Noida-based digital payments and financial services company was committed to being artificial intelligence-first in terms of its offerings and processes. As of June 2025, Paytm's market share was recorded at 6.9 per cent, according to data from the NPCI website. Sharma indicated that the company would continue to expand internationally. 'Our international expansion will be deliberate, with a long-term view and a 1,000-day commitment to meaningful results,' he said. This comes on the back of building 'value-accretive services' for the company's merchants to grow and retain customers. 'These are products that extend our stack and unlock monetisation beyond transactions. These solutions are already showing promise in India, and we're beginning to explore international opportunities where small businesses remain underserved,' he explained. At its meeting in March, the company's board of directors, based on the recommendations of the Nomination and Remuneration Committee, approved a fixed annual remuneration of ₹4 crore for Sharma, along with other company benefits, for the period from April 2025 to December 2027. His remuneration for 2024-25 (FY25) stood at ₹4.47 crore. One97 Communications, the company that operates the Paytm brand, reported a turnaround with a consolidated profit of ₹122.5 crore in the first quarter (Q1) of 2025–26, against a net loss of ₹838.9 crore in Q1FY25. Paytm had posted a net loss of ₹539.8 crore in the fourth quarter of FY25.